• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034).

作者信息

Prince H Miles, Hönemann Dirk, Spencer Andrew, Rizzieri David A, Stadtmauer Edward A, Roberts Andrew W, Bahlis Nizar, Tricot Guido, Bell Bill, Demarini Douglas J, Benjamin Suttle A, Baker Katherine L, Pandite Lini N

出版信息

Blood. 2009 May 7;113(19):4819-20. doi: 10.1182/blood-2009-02-207209.

DOI:10.1182/blood-2009-02-207209
PMID:19423744
Abstract
摘要

相似文献

1
Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034).血管内皮生长因子抑制并非复发或难治性多发性骨髓瘤的有效治疗策略：帕唑帕尼（GW786034）的2期研究
Blood. 2009 May 7;113(19):4819-20. doi: 10.1182/blood-2009-02-207209.
2
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).来那度胺、阿霉素和地塞米松（RAD）用于复发和难治性多发性骨髓瘤患者：德国骨髓瘤研究组DSMM（德国多发性骨髓瘤研究组）的报告
Blood. 2009 Apr 30;113(18):4137-43. doi: 10.1182/blood-2008-10-184135. Epub 2009 Jan 30.
3
A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma.一项关于Hsp90抑制剂KW-2478联合硼替佐米治疗复发/难治性多发性骨髓瘤患者的I/II期研究。
Br J Cancer. 2017 Oct 24;117(9):1295-1302. doi: 10.1038/bjc.2017.302. Epub 2017 Sep 5.
4
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.来那度胺治疗后复发或难治性多发性骨髓瘤患者的泊马度胺、硼替佐米和地塞米松治疗（OPTIMISMM）：一项随机、开放标签、3 期试验。
Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13.
5
Intra-patient dose escalation of panobinostat in patients with relapsed/refractory multiple myeloma.复发/难治性多发性骨髓瘤患者中帕比司他的患者内剂量递增
Leuk Lymphoma. 2018 May;59(5):1277-1278. doi: 10.1080/10428194.2017.1372579. Epub 2017 Sep 6.
6
A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma.重组环化TRAIL用于复发或难治性多发性骨髓瘤患者的1b期剂量递增研究。
Am J Clin Oncol. 2018 Oct;41(10):1008-1014. doi: 10.1097/COC.0000000000000404.
7
A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.一项关于法尼基西布联合硼替佐米及地塞米松治疗复发/难治性多发性骨髓瘤患者的1期剂量递增研究。
Cancer. 2016 Nov 15;122(21):3327-3335. doi: 10.1002/cncr.30174. Epub 2016 Jul 19.
8
A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.法尼基西布单药及联合低剂量地塞米松治疗复发/难治性多发性骨髓瘤的1/2期研究。
Cancer. 2017 Dec 1;123(23):4617-4630. doi: 10.1002/cncr.30892. Epub 2017 Aug 17.
9
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.伊布替尼联合卡非佐米/地塞米松治疗复发/难治性多发性骨髓瘤的 1/2b 期研究的最终分析。
Hematol Oncol. 2020 Aug;38(3):353-362. doi: 10.1002/hon.2723. Epub 2020 Mar 11.
10
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.新型研究性NEDD8激活酶抑制剂pevonedistat（MLN4924）用于复发/难治性多发性骨髓瘤或淋巴瘤患者的I期研究
Clin Cancer Res. 2016 Jan 1;22(1):34-43. doi: 10.1158/1078-0432.CCR-15-1237. Epub 2015 Nov 11.

引用本文的文献

1
Advancements in microenvironment-based therapies: transforming the landscape of multiple myeloma treatment.基于微环境疗法的进展：改变多发性骨髓瘤的治疗格局
Front Oncol. 2024 Jul 17;14:1413494. doi: 10.3389/fonc.2024.1413494. eCollection 2024.
2
Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM).多发性骨髓瘤（MM）的趋化因子/趋化因子受体轴在肿瘤生物学中的研究进展。
Cell Commun Signal. 2024 Mar 12;22(1):177. doi: 10.1186/s12964-024-01544-7.
3
The Clinical Relevance of Selected Cytokines in Newly Diagnosed Multiple Myeloma Patients.
新诊断多发性骨髓瘤患者中特定细胞因子的临床相关性
Biomedicines. 2023 Nov 9;11(11):3012. doi: 10.3390/biomedicines11113012.
4
Anti-Angiogenic Activity of Drugs in Multiple Myeloma.药物在多发性骨髓瘤中的抗血管生成活性。
Cancers (Basel). 2023 Mar 27;15(7):1990. doi: 10.3390/cancers15071990.
5
All Good Things Must End: Termination of Receptor Tyrosine Kinase Signal.好的事情终将结束：受体酪氨酸激酶信号的终止。
Int J Mol Sci. 2021 Jun 14;22(12):6342. doi: 10.3390/ijms22126342.
6
New Insights in Anti-Angiogenesis in Multiple Myeloma.多发性骨髓瘤抗血管生成的新见解。
Int J Mol Sci. 2018 Jul 12;19(7):2031. doi: 10.3390/ijms19072031.
7
Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma.酪氨酸激酶抑制剂作为多发性骨髓瘤的抗血管生成药物
Pharmaceuticals (Basel). 2010 Apr 22;3(4):1225-1231. doi: 10.3390/ph3041225.
8
Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.复发和难治性多发性骨髓瘤的耐药机制
Biomed Res Int. 2015;2015:341430. doi: 10.1155/2015/341430. Epub 2015 Nov 16.
9
Not too little, not too much-just right! (Better ways to give high dose melphalan).不多不少，恰到好处！（给予高剂量美法仑的更佳方法）
Bone Marrow Transplant. 2014 Dec;49(12):1457-65. doi: 10.1038/bmt.2014.186. Epub 2014 Aug 18.
10
Molecularly targeted therapies in multiple myeloma.多发性骨髓瘤的分子靶向治疗
Leuk Res Treatment. 2014;2014:976567. doi: 10.1155/2014/976567. Epub 2014 Apr 16.